
|Articles|January 9, 2006
R.Ph.s give thumbs-down to Rx-to-OTC switch of Xenical
Advertisement
The majority of pharmacists are not in favor of an Rx-to-OTC switch of Roche’s antiobesity drug Xenical (orlistat), judging from the results of a recent Instant Poll on Drug Topics’ Web site. To the question “Should a weaker-strength version of Xenical be approved over the counter for weight loss?” 63% of the 224 respondents gave a thumbs-down to a switch, 35% voted in favor of it, and about 2% said they don’t know.
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Pneumococcal Diseases Require Constant Vaccine Development | NCPA 2025
2
The Rise in Supplement Use Calls for Pharmacist-Led Counseling, Education | NCPA 2025
3
The Variety of Migraine Treatment Options Opens the Door for Pharmacy Services | NCPA 2025
4
Why Pharmacists Need to Put More Emphasis on Supplement Education | NCPA 2025
5